TWST - Twist Bioscience Corp Stock Price, Fair Value and News

$42.47+0.81 (+1.94%)

Delayed as of 22 Nov 2024, 11:04 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TWST Price Action

Last 7 days

6.8%

Last 30 days

-5.0%

Last 90 days

-4.7%

Trailing 12 Months

74.7%

TWST RSI Chart

TWST Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-11.85

Price/Sales (Trailing)

7.9

EV/EBITDA

-12.7

Price/Free Cashflow

-35.75

TWST Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TWST Fundamentals

TWST Revenue

Revenue (TTM)

313.0M

Rev. Growth (Yr)

26.53%

Rev. Growth (Qtr)

3.98%

TWST Earnings

Earnings (TTM)

-208.7M

Earnings Growth (Yr)

25.06%

Earnings Growth (Qtr)

59.5%

TWST Profitability

Operating Margin

42.61%

EBT Margin

-66.51%

Return on Equity

-44.16%

Return on Assets

-33.98%

Free Cashflow Yield

-2.8%

TWST Investor Care

Shares Dilution (1Y)

3.13%

Diluted EPS (TTM)

-3.6

TWST Alerts

5 major insider sales recently.
Invesco Ltd. reported owning 6.3% of TWST [2024-11-08]
Big jump in Revenue (Y/Y)
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	277.5M	295.2M	313.0M	0
2023	227.8M	235.5M	245.1M	262.4M
2022	163.1M	184.2M	203.6M	215.8M
2021	113.0M	126.8M	132.3M	146.2M
2020	65.8M	73.4M	90.1M	101.1M
2019	40.0M	47.1M	54.4M	60.1M
2018	18.1M	21.8M	25.4M	32.6M
2017	0	0	10.8M	14.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Twist Bioscience Corp

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

CEO	Dr. Emily Marine Leproust Ph.D.
WEBSITE	twistbioscience.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	989

Twist Bioscience Corp Frequently Asked Questions

What is the ticker symbol for Twist Bioscience Corp? What does TWST stand for in stocks?

TWST is the stock ticker symbol of Twist Bioscience Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Twist Bioscience Corp (TWST)?

As of Thu Nov 21 2024, market cap of Twist Bioscience Corp is 2.47 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TWST stock?

You can check TWST's fair value in chart for subscribers.

Is Twist Bioscience Corp a good stock to buy?

The fair value guage provides a quick view whether TWST is over valued or under valued. Whether Twist Bioscience Corp is cheap or expensive depends on the assumptions which impact Twist Bioscience Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TWST.

What is Twist Bioscience Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 21 2024, TWST's PE ratio (Price to Earnings) is -11.85 and Price to Sales (PS) ratio is 7.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TWST PE ratio will change depending on the future growth rate expectations of investors.